Novo Nordisk’s NVO oral obesity pill, amycretin, showed faster weight loss than its blockbuster weekly injection, Wegovy (semaglutide), in a phase I study. Not only did NVO’s stock rise 4% in response ...
Novo Nordisk’s NVO oral obesitypill, amycretin, showed faster weight loss than its blockbuster weekly injection, Wegovy (semaglutide), in a phase I study. Not only did NVO’s stock rise 4% in ...
Results that may be inaccessible to you are currently showing.